The estimation of efficiency of consecutive application of radioprotector B-190 and interleukin-1beta administered at early times after acute irradiation by studying the changes of the number of peripheral blood leukocytes, neutrophils and lymphocytes, as well as cytochemical research into the contents of glycogen, myeloperoxidase and alkaline phosphatase in neutrophils of the irradiated mice was carried out. It is established that administration of radioprotector B-190 at a doze of 50 mg/kg for 15 minutes before irradiation and interleukin-1beta at a doze of 50 mkg/kg for 15 minutes after irradiation reduces the expressiveness of post-irradiation leukopenia, accelerates restoration of the number of neutrophils and lymphocytes in peripheral blood, normalizes the functional status of neutrophils of irradiated mice to a greater degree than their isolated introduction.

The study was aimed at evaluating the radioprotective effectiveness of genistein administered at different times before or after acute irradiation. Evaluation ofradioprotective efficiency was performed by studying the 30-day survival rate, life expectancy, bone marrow hemapoiesis using the method of endogenous and exogenous colony formation. We have established that genistein at a dose of 200 mg/kg when administered 1 hour prior to irradiation has the highest radioprotective efficiency. In this case, genistein protects mice against death due to X-ray radiation at doses LD(50-90/30), increasing their survival rate by 30-44%, and reduces expression of post radiation disorders of bone marrow hematopoiesis.

Проведена оценка радиозащитной эффективности отечественного синтетического препарата генистеина при его введении в разные сроки до или после радиационного воздействия путем изучения 30-суточной выживаемости, средней продолжительности жизни погибших животных, исследования костномозгового кроветворения облученных мышей в методике эндо- и экзогенного колониеобразования. Установлено, что генистеин в дозе 200 мг/кг при введении за 1 ч до облучения обладает наибольшей радиозащитной эффективностью. При этом он снижает постлучевую гибель мышей, подвергнутых рентгеновскому облучению в дозах СД50-90/30, увеличивая их выживаемость на 30–44%, а также уменьшает выраженность постлучевых нарушений костномозгового кроветворения.

Medical antiradiation protection is one of the key factors determining fighting capacity of armies. The basis of medical protection in the countries of the NATO is made with the preparations used up to an irradiation (radioprotector WR-2721) and at the first time after radiating influence. The Russian system of antiradiation protection includes radioprotectors, drugs for prophylaxis and treatment of syndrome of primary reaction to an irradiation, means of early therapy of radiation injure, preparations for sorption and elimination of radionuclides, got in an organism.

The purpose of research was the experimental estimation of efficiency of consecutive application of a radioprotector B-190 and means of emergency therapy of radiating injury interleukin-1beta at acute irradiation. An estimation of treatment-and-prophylactic action of the given circuit of introduction of preparations carried out by studying 30 day-survival and average life expectancy of the lost animals, research of bone marrow hemopoiesis. It is established, that consecutive application of a radioprotector B-190 in a doze of 50 mg/kg for 15 mines up to an irradiation and interleukin-1beta in a doze of 50 mkg/kg through 15 mines after irradiating increases survival and prevents decrease in quantity of CFU-S9 at the irradiated mice in the greater degree, than their isolated introduction.